Teens whose mothers had gestational diabetes are at greater risk of type 2 diabetes
Obese teenagers whose mothers had gestational diabetes while pregnant with them are at greater risk of developing Type 2 diabetes, a new study shows.
Fifteen injuries linked to defective jaw implant; device has been recalled
Certain implants used in adults, children and infants to lengthen and stabilize the lower jawbone or side jaw to correct birth defects or post-traumatic defects are being recalled because the device may reverse direction. To date, this device defect has
Drug companies race for FDA approval on new class of cholesterol lowering drugs
Pharmaceutical companies are in a desperate race to get their new type of cholesterol-lowering treatment reviewed and approved by drug regulators so they can be the first to hit the market and take a bite out of the multibillion-dollar statin
New testosterone treatment in development carries fewer side effects
Testosterone levels in men typically drop as a man ages, but when it drops too low it signals a possible problem. In many cases the drop can be associated with obesity, diabetes and circulatory disease.
Combining old diabetes drug with new improves blood sugar control
Combining the commonly used metformin with another class of medication can greatly improve blood sugar control in Type 2 diabetics, according to new research.
Young, African-American dialysis patients at greater risk of dying
Young African-Americans on dialysis are 1.5 times more likely to die than white dialysis patients, according to a study published in the Journal of the American Society of Nephrology.
Hundreds of Risperdal gynecomastia lawsuits filed in Philadelphia court
About 700 product liability lawsuits involving the antipsychotic Risperdal have been filed in Philadelphia Court of Common Pleas alleging use of the drug caused boys and young men to develop breasts, a condition referred to as gynecomastia. Many of the
Drug company testing type 2 diabetes drug designed to have fewer side effects
Drug developer BioKier currently testing a new oral formulation of type 2 diabetes treatment that may prove safer than injectable versions of the drug currently on the market.
Regeneron, Sanofi pay $67.5 million to expedite approval of experimental cholesterol drug
Regeneron Pharmaceuticals and Sanofi are paying $67.5 million to improve the chances of getting their experimental cholesterol-lowering drug on the market before any other drug company with similar cholesterol treatments in development. Regeneron and Sanofi are purchasing a first-of-its-kind voucher